Oxygen supply onboard

The provision of oxygen therapy onboard is a common and crucial intervention prescribed by our clinicians when caring for hypoxic patients. This supplementation typically involves the use of a low-flow nasal cannula (LFNC), although there are limitations to this approach. Traditionally, LFNCs can only effectively deliver up to 4 to 6 liters per minute of supplemental oxygen, resulting in a FiO2 range of approximately 0.37 to 0.45. Beyond this range, nasal mucosal irritation may occur, leading to potential bleeding with prolonged use. Moreover, LFNC therapy's efficacy is limited due to the open system, resulting in high levels of leaking air around the oxygen source
To address these limitations, we offer high-flow nasal cannula (HFNC) therapy, capable of delivering up to 100% humidified and perfect temperature oxygen at flow rates of up to 60 liters per minute. HFNC therapy allows for greater control over the delivery of supplemental oxygen, with all settings controlled independently. This not only enhances confidence in oxygen delivery but also leads to improved outcomes for patients. Additionally, HFNC therapy offers several benefits beyond LFNC, including a more efficient physiological mechanism of action.
Independent control of all settings ensures increased confidence in the delivery of supplemental oxygen and leads to improved outcomes. Apart from enhanced control over FiO2 delivery, there are numerous benefits associated with the use of a high-flow nasal cannula. Our team delves into the physiological mechanism of action and various applications of high-flow nasal cannula therapy. We conduct thorough reviews of its utilization and emphasize the crucial role of the professional team in evaluating and monitoring patients undergoing high-flow oxygen therapy. Trust our expertise in optimizing the use of high-flow nasal cannulas to achieve the best possible outcomes for patients.